CRANBURY, N.J., Aug. 3, 2026
Rocket Pharmaceuticals, Inc. announced a positive clinical safety update from the first three patients treated with its investigational gene therapy RP-A501 under a modified Phase 2 pivotal trial protocol for Danon disease, a rare inherited disorder that causes progressive heart failure. According to the company, all three patients were treated safely with the revised dosing regimen, and no cases of thrombotic microangiopathy (TMA), capillary leak syndrome, or other significant safety concerns have been observed to date. The encouraging early findings support continued advancement of the program as Rocket works closely with the U.S. Food and Drug Administration (FDA) to align on the regulatory pathway for enrolling additional patients and completing the pivotal study. The company expects to provide a broader Danon disease program update and regulatory guidance during the second half of 2026.
Modified Phase 2 Protocol Demonstrates Encouraging Early Safety
The initial patients received RP-A501 at a recalibrated dose of 3.8 × 10¹³ genome copies per kilogram (GC/kg) together with a refined immunomodulatory regimen consisting of rituximab, sirolimus, and corticosteroids. Patient dosing was performed sequentially with at least four weeks between infusions, allowing close evaluation of safety before treating additional participants. The ongoing single-arm pivotal Phase 2 study is designed to enroll 12 patients with Danon disease, an ultra-rare inherited cardiomyopathy. Based on the favorable safety profile observed in the first three participants, Rocket is actively engaging with the FDA to determine the path forward for dosing the remaining patients while maintaining the modified protocol designed to optimize treatment safety.
RP-A501 Gene Therapy Targets the Underlying Cause of Danon Disease
RP-A501 is an investigational AAV9-based gene therapy developed to address the genetic cause of Danon disease by delivering a functional LAMP2B gene directly to cardiac muscle cells through a single intravenous infusion. The therapy is designed to restore the function of the lysosome-associated membrane protein 2B (LAMP2B), whose deficiency leads to impaired autophagy, progressive cardiac damage, and ultimately heart failure. Previous Phase 1 clinical results demonstrated meaningful improvements in cardiac structure and function, supporting advancement into the pivotal Phase 2 study. The program has received multiple important regulatory incentives, including Regenerative Medicine Advanced Therapy (RMAT), Fast Track, Rare Pediatric Disease, and Orphan Drug Designations from the FDA, as well as Advanced Therapy Medicinal Product (ATMP) and PRIME designations in Europe.
Advertisement
Regulatory Discussions Continue as Rocket Advances Rare Disease Program
Rocket Pharmaceuticals is continuing discussions with the FDA to establish the regulatory pathway for completing the pivotal Phase 2 trial, with an update expected later in 2026. The company believes the recalibrated dosing strategy preserves the therapeutic potential demonstrated in earlier clinical studies while improving the overall benefit-risk profile by accounting for manufacturing-related differences in vector composition. As one of the first gene therapies to demonstrate promising clinical outcomes for an inherited cardiovascular disorder, RP-A501 represents a potentially transformative treatment for patients with Danon disease, where heart transplantation remains the only definitive treatment option. The program also strengthens Rocket’s broader portfolio of genetic medicines targeting rare inherited cardiovascular diseases with significant unmet medical needs.
Source:Rocket Pharmaceuticals press release
